T. Rowe Price Associates
PRCT icon

T. Rowe Price Associates’s Procept Biorobotics PRCT Stock Holding History

T. Rowe Price Associates’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.1M Buy
1,332,452
+726,494
+120% +$18.2M ﹤0.01% 1030
2026
Q1 		$15.2M Sell
605,958
-99,782
-14% -$2.81M ﹤0.01% 1118
2025
Q4 		$22.2M Sell
705,740
-169,441
-19% -$5.62M ﹤0.01% 1048
2025
Q3 		$31.2M Sell
875,181
-447,258
-34% -$20.4M ﹤0.01% 941
2025
Q2 		$76.2M Buy
1,322,439
+266,677
+25% +$15.1M 0.01% 627
2025
Q1 		$61.5M Buy
1,055,762
+341,906
+48% +$23.3M 0.01% 661
2024
Q4 		$57.5M Sell
713,856
-63,574
-8% -$5.43M 0.01% 716
2024
Q3 		$62.3M Sell
777,430
-391,872
-34% -$27.8M 0.01% 697
2024
Q2 		$71.4M Sell
1,169,302
-298,357
-20% -$17.7M 0.01% 615
2024
Q1 		$72.5M Sell
1,467,659
-38,000
-3% -$1.81M 0.01% 620
2023
Q4 		$63.1M Sell
1,505,659
-250,844
-14% -$8.54M 0.01% 636
2023
Q3 		$57.6M Buy
1,756,503
+225,163
+15% +$7.68M 0.01% 642
2023
Q2 		$54.1M Buy
1,531,340
+187,575
+14% +$6.2M 0.01% 682
2023
Q1 		$38.2M Buy
1,343,765
+175,148
+15% +$6.18M 0.01% 755
2022
Q4 		$48.5M Buy
1,168,617
+97,383
+9% +$4.18M 0.01% 668
2022
Q3 		$44.4M Sell
1,071,234
-2,832,769
-73% -$113M 0.01% 683
2022
Q2 		$128M Buy
3,904,003
+58,511
+2% +$2.13M 0.02% 592
2022
Q1 		$135M Buy
3,845,492
+2,442,421
+174% +$58.8M 0.01% 639
2021
Q4 		$34.1M Buy
1,403,071
+62,087
+5% +$2.3M ﹤0.01% 1133
2021
Q3 		$49.7M Buy
+1,340,984
New +$51.5M ﹤0.01% 1013

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates's PRCT Position: Q2 2026 in Review

T. Rowe Price Associates increased its Procept Biorobotics (PRCT) stake by 120% in Q2 2026, buying an estimated $18.2M and bringing the position to 1,332,452 shares worth $30.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1030.

T. Rowe Price Associates first reported a position in PRCT in Q3 2021 and has held it in 20 quarters since. The position peaked at $135M in Q1 2022. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • T. Rowe Price Associates held 1,332,452 shares of Procept Biorobotics worth $30.1M as of Q2 2026.
  • T. Rowe Price Associates bought 726,494 Procept Biorobotics shares in Q2 2026, an estimated $18.2M.
  • Procept Biorobotics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1030 holding.
  • T. Rowe Price Associates first reported a position in Procept Biorobotics in Q3 2021 and has held it in 20 quarters since.
  • T. Rowe Price Associates's Procept Biorobotics position peaked at $135M in Q1 2022.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.